Premium
A CONTROLLED TRIAL ON CLONAZEPAM INN (Ro 5‐4023, RIVOTRIL (R) ) IN THE TREATMENT OF FOCAL EPILEPSY AND SECONDARY GENERALIZED GRAND MAL EPILEPSY
Author(s) -
Mikkelsen B.,
BirketSmith E.,
Holm P.,
Lund M.,
Vestermark S.,
Olsen P. Zander
Publication year - 1975
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1975.tb01390.x
Subject(s) - clonazepam , epilepsy , placebo , somnolence , grand mal , generalized epilepsy , anesthesia , medicine , adverse effect , psychiatry , alternative medicine , pathology
In a controlled clinical investigation based on 14 patients with focal seizures and 3 patients with secondary generalized grand mal epilepsy, all with insufficient response to conventional anti‐epileptic treatment, clonazepam (Rivotril (R) ) combined with previous anti‐epileptic drugs was compared with placebo combined with the same drugs. The trial was singleblind cross‐over with sequential analyses. With a daily dose, depending upon age, of usually 3–6 mg, the anti‐epileptic effect of Clonazepam was significantly superior to placebo and was estimated as remarkably good. Side‐effects in the form of somnolence, fatigue, drowsiness and co‐ordination disturbances occurred in most of the patients but subsided spontaneously or could be managed by slow increase or slight reduction in dosage.